[HTML][HTML] Pharmacokinetics and drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine
D Hodge, DJ Back, S Gibbons, SH Khoo… - Clinical …, 2021 - Springer
Combined antiretroviral treatments have significantly improved the morbidity and mortality
related to HIV infection, thus transforming HIV infection into a chronic disease; however, the …
related to HIV infection, thus transforming HIV infection into a chronic disease; however, the …
[HTML][HTML] Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells
D Hodge, LL Glass, E Diakogiannaki, R Pais… - Peptides, 2016 - Elsevier
Aims/hypothesis Glucagon-like peptide-1 (GLP-1) is an incretin hormone derived from
proglucagon, which is released from intestinal L-cells and increases insulin secretion in a glucose …
proglucagon, which is released from intestinal L-cells and increases insulin secretion in a glucose …
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
D Hodge, F Marra, C Marzolini, A Boyle… - Journal of …, 2020 - academic.oup.com
As global health services respond to the coronavirus pandemic, many prescribers are turning
to experimental drugs. This review aims to assess the risk of drug–drug interactions in the …
to experimental drugs. This review aims to assess the risk of drug–drug interactions in the …
[HTML][HTML] VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis
N Beazley-Long, D Hodge, WR Ashby… - Brain, behavior, and …, 2018 - Elsevier
Chronic pain can develop in response to conditions such as inflammatory arthritis. The central
mechanisms underlying the development and maintenance of chronic pain in humans are …
mechanisms underlying the development and maintenance of chronic pain in humans are …
Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion
F Reimann, E Diakogiannaki, D Hodge, FM Gribble - Peptides, 2020 - Elsevier
Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone secreted from the
upper small intestine, which plays an important physiological role in the control of glucose …
upper small intestine, which plays an important physiological role in the control of glucose …
Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature
D Hodge, EM Hodel, E Hughes… - JAIDS Journal of …, 2023 - journals.lww.com
Background: Contemporary first-line antiretrovirals have considerably reduced liability for
clinically significant drug–drug interactions (DDI). This systematic review evaluates the …
clinically significant drug–drug interactions (DDI). This systematic review evaluates the …
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data
…, A Williams, T Pham, S Khoo, D Hodge… - Clinical …, 2023 - Springer
Introduction Metabolic inducers can expose people with polypharmacy to adverse health
outcomes. A limited fraction of potential drug–drug interactions (DDIs) have been or can …
outcomes. A limited fraction of potential drug–drug interactions (DDIs) have been or can …
[HTML][HTML] PBPK modelling of dexamethasone in patients with COVID-19 and liver disease
MC Montanha, N Cottura, M Booth, D Hodge… - Frontiers in …, 2022 - frontiersin.org
The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling
to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (…
to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (…
Incorporating Transgender and nonbinary Participants in Phase 1 Clinical Drug Trials: Current Knowledge Gaps and Considerations for Phase 1 Studies
L Walker, M Stackpoole, D Hodge, R FitzGerald - 2024 - europepmc.org
Phase 1 clinical drug trials critically depend on the participation of healthy volunteers to
evaluate the safety and pharmacokinetics of new medicinal products. Current selection criteria …
evaluate the safety and pharmacokinetics of new medicinal products. Current selection criteria …
Correction to: Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
D Hodge, F Marra, C Marzolini, A Boyle… - J Antimicrob …, 2022 - ncbi.nlm.nih.gov
… Daryl Hodge, Fiona Marra, Catia Marzolini, Alison Boyle, Sara Gibbons, Marco Siccardi,
David Burger, David Back, Saye Khoo, Drug interactions: a review of the unseen danger of …
David Burger, David Back, Saye Khoo, Drug interactions: a review of the unseen danger of …